Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders

Psychopharmacology

Volumn 234, Issue 16, 2017, Pages 2443-2452

  Murphy, Cara M ^a   MacKillop, James ^a,b   Martin, Rosemarie A ^a   Tidey, Jennifer W ^a   Colby, Suzanne M ^a   Rohsenow, Damaris J ^a,c  

^a BROWN UNIVERSITY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abstinence; Behavioral economics; Cigarette purchase task; Nicotine dependence; Nicotine replacement therapy; Smoking; Substance use disorders; Varenicline

Indexed keywords

NICOTINE; PLACEBO; VARENICLINE;

ADULT; ARTICLE; BEHAVIORAL ECONOMICS; CIGARETTE PURCHASE TASK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; FEMALE; HEALTH CARE NEED; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PURCHASING; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; THERAPY EFFECT; COMPARATIVE STUDY; CRAVING; CUTANEOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; REINFORCEMENT; SMOKING; SMOKING PREVENTION; THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; CRAVING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; REINFORCEMENT (PSYCHOLOGY); SMOKING; SMOKING CESSATION; SMOKING PREVENTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VARENICLINE;

EID: 85019238176     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-017-4635-4     Document Type: Article

References (32)

1. Anthenelli RM, Benowitz NL, West R, et al. (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet
2. Cahill K, Stevens S, Lancaster T (2014) Pharmacological treatments for smoking cessation. JAMA: the journal of the American Medical Association 311(2):193
3. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates.
4. Ellingstad TP, Sobell LC, Sobell MB, Cleland PA, Agrawal S (1999) Alcohol abusers who want to quit smoking: implications for clinical treatment. Drug Alcohol Depend 54(3):259–265
5. First MB, Spitzer RL, Williams JBW, Gibbon M (1997) Structured clinical interview of DSM-IV disorders (SCID). American Psychiatric Association, Washington, DC
6. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS (2011) A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 215(4):655–663
7. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86:1119–1127
8. Hursh SR, Silberberg A (2008) Economic demand and essential value. Psychol Rev 115(1):186–198. doi:10.1037/0033-295x.115.1.186
9. Jacobs EA, Bickel WK (1999) Modeling drug consumption in the clinic using simulation procedures: demand for heroin and cigarettes in opioid-dependent outpatients. Exp Clin Psychopharmacol 7(4):412–426. doi:10.1037/1064-1297.7.4.412
10. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24(2):97–129
11. Leeman RF, Huffman CJ, O'Malley SS (2007) Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol 42(3):196–206
12. Littleton J, Barron S, Prendergast M, Nixon SJ (2007) Smoking kills (alcoholics)! Shouldn’t we do something about it? Alcohol Alcohol 42(3):167–173
13. MacKillop J, Tidey JW (2011) Cigarette demand and delayed reward discounting in nicotine-dependent individuals with schizophrenia and controls: an initial study. Psychopharmacology 216(1):91–99
14. MacKillop J, Murphy JG, Ray LA et al (2008) Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers. Exp Clin Psychopharmacol 16(1):57–65. doi:10.1037/1064-1297.16.1.57
15. MacKillop J, Murphy JG, Tidey JW, Kahler CW, Ray LA, Bickel WK (2009) Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology 203(1):33–40. doi:10.1007/s00213-008-1367-5
16. MacKillop J, Murphy CM, Martin RA et al (2016) Predictive validity of a cigarette purchase task in a randomized controlled trial of contingent vouchers for smoking in individuals with substance use disorders. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 18(5):531–537. doi:10.1093/ntr/ntv233
17. Madden GJ, Kalman D (2010) Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking. Nicotine Tob Res 12(4):416–422
18. McClure EA, Vandrey RG, Johnson MW, Stitzer ML (2013) Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob Res 15(1):139–148. doi:10.1093/ntr/nts101
19. Murphy JG, MacKillop J, Tidey JW, Brazil LA, Colby SM (2011) Validity of a demand curve measure of nicotine reinforcement with adolescent smokers. Drug Alcohol Depend 113(2):207–214
20. National Institute on Drug Abuse (2011) Treatment statistics. Revised March 2011 edn. National Institute on Drug Abuse
21. Prochaska JO, Velicer WF, Rossi JS et al (1994) Stages of change and decisional balance for 12 problem behaviors. Health Psychol 13(1):39–46. doi:10.1037/0278-6133.13.1.39
22. Prochaska JJ, Delucchi K, Hall SM (2004) A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. American Psychological Assn
23. Richter KP, Ahluwalia HK, Mosier MC, Nazir N, Ahluwalia JS (2002) A population-based study of cigarette smoking among illicit drug users in the United States. Addiction 97(7):861–869. doi:10.1046/j.1360-0443.2002.00162.x
24. Rohsenow DJ, Tidey JW, Martin RA, et al. (in press) Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction
25. Schlienz NJ, Hawk LW Jr, Tiffany ST, O'Connor RJ, Mahoney MC (2014) The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement. Addict Behav 39(10):1484–1490. doi:10.1016/j.addbeh.2014.05.008
26. Secades-Villa R, Pericot-Valverde I, Weidberg S (2016) Relative reinforcing efficacy of cigarettes as a predictor of smoking abstinence among treatment-seeking smokers. Psychopharmacology. doi:10.1007/s00213-016-4350-6
27. Smith TT, Cassidy RN, Tidey JW, et al. (2016) Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial. Addiction
28. Stein MD, Anderson BJ, Niaura R (2006) Nicotine replacement therapy: patterns of use after a quit attempt among methadone-maintained smokers. J Gen Intern Med 21(7):753–757
29. Stein M, Caviness C, Kurth M, Audet D, Olson J, Anderson B (2013) Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend 133(2):486–493
30. Tabachnick BG, Fidell LS (2007) Using multivariate statistics, 5th edn. Allyn & Bacon/Pearson Education, Boston
31. Tapper AR, McKinney SL, Nashmi R et al (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306(5698):1029–1032
32. Thurgood SL, McNeill A, Clark-Carter D, Brose LS (2015) A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine & Tobacco Research:ntv127